EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Yuho Ebata iD, Koji Ando iD, Hirofumi Hasuda, Koshi Mimori, Elizabeth C Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi

Molecular Oncology · 2026-08 · 20 (8) · 2114-2128

DOI: 10.1002/1878-0261.70256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 15.04.2026. Verfasst von Yuho Ebata und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Boron Compounds, Drug Resistance, Neoplasm, Glycine, Colorectal Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge. We previously showed that camptothecin induces ubiquitin–proteasome pathway (UPP)‐mediated topoI degradation. In this study, we investigated whether inhibition of UPP could prevent topoI degradation and restore camptothecin sensitivity. SN‐38, an active metabolite of irinotecan, induced topoI degradation in irinotecan‐resistant colorectal cancer cell lines, which was suppressed by ixazomib. The combination significantly enhanced cytotoxicity, colony inhibition, and reduced IC 50 values compared with SN‐38 alone. Mechanistically, ixazomib prevented proteasome‐mediated degradation of ubiquitinated topoI, restoring its stability. In vivo, the combination significantly suppressed tumor growth in a DLD‐1 xenograft model compared with SN‐38 alone. These findings indicate that UPP‐dependent topoI degradation is a key mechanism underlying irinotecan resistance in colorectal cancer. Pharmacological inhibition of the proteasome effectively prevents topoI loss and restores irinotecan sensitivity, suggesting that proteasome inhibitors such as ixazomib may serve as promising therapeutic partners for camptothecin‐based chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Boron CompoundsDrug Resistance, NeoplasmGlycineColorectal NeoplasmsProteasome InhibitorsCamptothecinDNA Topoisomerases, Type IProteolysisTopoisomerase I InhibitorsHumansIrinotecanAnimalsCell Line, TumorMice, NudeXenograft Model Antitumor AssaysProteasome Endopeptidase ComplexMice

Stichwörter der Autor:innen

SN‐38colorectal canceririnotecan resistanceixazomibproteasome inhibitortopoisomerase I

Substanzen

ixazomibBoron CompoundsGlycineIrinotecanProteasome InhibitorsCamptothecinDNA Topoisomerases, Type IProteasome Endopeptidase ComplexTopoisomerase I Inhibitors

Autor:innen und Institutionen

  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Gastroenterological Surgery and Clinical Research Institute, Kyushu Medical Center, Fukuoka, Japan.
  • Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan.
  • Department of Medicine, Division of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
  • Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Department of Advanced Medicine and Innovative Technology, Kyushu University Hospital, Fukuoka, Japan.

ORCID-Profile: Yuho Ebata, Koji Ando

Zitieren

APA

Ebata, Y., Ando, K., Hasuda, H., Mimori, K., Unan, E. C., Pulukuri, S., Tiku, A., Berger, A., Oki, E., Bharti, A., & Yoshizumi, T. (2026). Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer. Molecular Oncology, 20(8), 2114-2128. https://doi.org/10.1002/1878-0261.70256

Vancouver

Ebata Y, Ando K, Hasuda H, Mimori K, Unan EC, Pulukuri S, et al. Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer. Molecular Oncology. 2026;20(8):2114-2128. doi:10.1002/1878-0261.70256

BibTeX
@article{Ebata2026,
  author = {Ebata, Yuho and Ando, Koji and Hasuda, Hirofumi and Mimori, Koshi and Unan, Elizabeth C and Pulukuri, Siddhartha and Tiku, Aahana and Berger, Allison and Oki, Eiji and Bharti, Ajit and Yoshizumi, Tomoharu},
  title = {Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {8},
  pages = {2114--2128},
  doi = {10.1002/1878-0261.70256}
}
Kostenlos starten →